PCL, a leading biotechnology company based in South Korea, has consolidated its position as a pioneer in the field of multiplex in vitro diagnostics (IVD). Since its inception in 2008, PCL has been at the forefront of IVD multiplex screening, thanks to its revolutionary proprietary SG Cap technology, which specialized in the simultaneous detection of high-risk viruses. With renowned K-GMP and ISO 13485 certifications, PCL maintains an unwavering commitment to strict quality standards.
At the core of PCL's innovative approach is its cutting-edge SG Cap technology, which enables maximum protein capacity to be achieved in a small space, resulting in exceptional sensitivity. This advance enables up to 64 diagnostics to be performed in a single space, reducing costs, time, space and waste, while guaranteeing superior diagnostic results.
PCL's product portfolio includes, the HISU solution for high risk viruses screening including HIV at the same time. can be screened at one time, which is a fully automated multiplex immunoassay platform for mass screening, accommodating up to 540 tests. Thanks to SG Cap technology, HISU offers outstanding speed, environmental friendliness, and simultaneous detection of multiple high-risk viruses. HISU offers blood bank screening, multiple cancer screening, and serves as a compatible ELISA open system, providing a comprehensive diagnostic solution.
The PCLOK II portable immunoassay system is designed for small and medium-sized hospitals, pet clinics and healthcare centers. Within 30 minutes, PCLOK II enables operators to test 6 samples at the same time, enabling multiplex screening for high risk blood banks, cancer diagnostics, pet antibody detection and respiratory viruses screening. In 2023, PCL introduced a revolutionary comprehensive reagent capable of detecting 6 respiratory viruses simultaneously: Flu A, Flu B, COVID-19, RSV, Adenovirus, and Parainfluenza. This breakthrough is a major step toward preventing the spread of respiratory viruses.
As a respond to the COVID-19 crisis, PCL's Pandemic solution meets the urgent need for rapid, accurate diagnostics. This comprehensive offering includes a COVID-19 antigen rapid kit using saliva samples, an RT-PCR kit and antibody detection kit. In Fact, PCL was the first to develop the first COVID-19 antigen test using human saliva samples (PCL COVID19 Ag Gold), a user-friendly test delivering results in 10 minutes. This convenient and innovative kit has been successfully supplied in over 50 countries worldwide, facilitating effective pandemic management.
Continuing its commitment to innovation, PCL is committed to revolutionizing in vitro multiplex diagnostics, guaranteeing accurate and effective tests for a wide range of diseases. PCL's unwavering pursuit of excellence underscores its significant contribution to global healthcare.
For more info, visit: www.pclchip.com or contact: pclchip@pclchip.com